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Abstract
Magnetic resonance spectroscopy (MRS) provides useful information regarding metabolic 
composition in the tissues, and advanced spectroscopic methods are used to quantify mark-
ers of tumor membrane turnover and proliferation (e.g., choline (Cho)), energy homoeo-
stasis (e.g., creatine (Cr)), intact glioneuronal structures (e.g., N-acetylaspartate (NAA)), 
and necrosis (e.g., lactate (Lac) or lipids). Results are usually expressed as metabolite ratios 
rather than absolute metabolite concentrations. Because glial tumors have some specific 
metabolic characteristics that differ according to the grade of tumor, there is a potential for 
MR spectroscopy to increase the sensitivity of routinely used diagnostic imaging. MRS also 
has many diagnostic applications in neurosciences to support the diagnosis in conditions 
like demyelination, infections, and dementia and in postradiotherapy cases. Biochemical 
changes in the metabolism of tumor cells related to malignant transformation are reflected 
in changes of particular metabolite concentration in the tumor tissue. Our prospective 
study aimed to analyze the usefulness of proton MR spectroscopy in grading of glioma 
and to correlate various metabolite ratios like choline/creatine, choline/N-acetylaspartate, 
N-acetylaspartate/creatine, and lactate/creatine with the histopathological grades of glioma.
Keywords: MRS, MRI, grade, glioma, NAA, choline, creatine, ratio
1. Introduction
Magnetic resonance spectroscopy (MRS) is an analytical method used for the identification 
and quantification of metabolites. It differs from conventional magnetic resonance imaging 
(MRI) since it provides physiological and chemical information instead of only anatomy [1].
© 2018 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.
Many of nuclei have been used to obtain MR spectra; few of them include proton (1H), phos-
phorus (31P), fluorine (19F), carbon (13C), and sodium (23Na).
Proton (1H) MR spectroscopy is most commonly used since hydrogen nucleus is abundant in 
human tissues [1].
Magnetic field strength clinically used for conventional MRI ranges from 0.2 to 3 T.
For MRS, higher-field strength (1.5 T or more) is required since the main aim of MRS is to 
detect weaker signals from metabolites. Higher-field strength units have the advantage of 
higher signal-to-noise ratio (SNR), better resolution, and shorter acquisition times.
2. Metabolites in MRS
2.1. N-Acetylaspartate (NAA)
N-Acetylaspartate (NAA) peak is the most prominent peak in normal adult brain proton MRS 
which resonates at 2.0 ppm [2] (Figure 1).
NAA is a derivative of aspartic acid. It is synthesized and stored primarily in the neurons and 
hence it is called a neuronal marker or a marker of neuronal density and viability [2].
As a neuronal marker, NAA concentration declines with the destruction of neurons in high-
volume lesions, dementia, hypoxia, or multiple sclerosis.
Due to the relationship between the decline in NAA concentration and increasing glioma 
grade, it is possible to use NAA as a substantial marker [13]. A high level of NAA is associated 
with a good prognosis [3].
NAA is also helpful for the differentiation of primary brain tumors from metastasis and non-
neuronal tumors where the metabolite is lacking in the spectra [4].
2.2. Creatine (Cr)
Creatine (Cr) is synthesized from amino acids primarily in the kidneys and liver and trans-
ported to the peripheral organs by blood and is called as energy metabolism marker [3].
Total Cr indicates the quantity of phosphocreatine (PCr) and Cr contained in neurons and 
glial cells and visualized as a prominent peak in MR spectra at 3.0 ppm; an additional peak 
for creatine may be visible at 3.94 ppm [3].
A decrease in the Cr level in high-grade gliomas (HGGs) is due to increased metabolic 
demands of the tumorous tissue in the brain. Cr is a relatively constant element of cellular 
energetic metabolism of the brain and it is frequently used as a reference metabolite for in vivo 
MRS, for example, for mainly calculating the metabolite ratios such as choline (Cho)/Cr, 
NAA/Cr, lipid (Lip)-lactate (Lac)/Cr, or myoinositol/Cr [3].
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2.3. Choline (Cho)
Choline (Cho) is a metabolic marker of cellular proliferation and cell membrane integrity, that 
is, phospholipids synthesis and degradation. Choline peak is seen at 3.2 ppm and is the most 
important metabolic peak for the diagnosis of a glioma [3].
Figure 1. Normal spectra obtained with short TE sequence (TE = 30 ms). Ins dd1, myoinositol; Cho, choline; Cr, creatine; 
Glx, glutamate glutamine; NAA, N-acetylaspartate [9].
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Increased choline reflects increased cell membrane synthesis and degradation. Thus, all pro-
cesses resulting in increased membrane turnover like primary brain neoplasm and myelin 
breakdown like demyelinating lesions lead to increased choline concentration [5].
2.4. Myoinositol (Myo)
Myoinositol (Myo) is a simple sugar assigned at 3.56 ppm.
It is considered as a glial marker because it is primarily synthesized in glial cells, almost only 
in astrocytes. It is also the most important osmolyte in astrocytes [3].
The elevation in Myo detected can be found in cerebral diseases associated with marked glio-
sis. Myo concentration is higher in low-grade glioma (LGG) when compared to high-grade 
glioma. Thus, a higher Myo/Cr ratio is seen in low-grade glioma [6].
2.5. Lactate (lac) and lipids (lip)
Lactate (Lac) and lipids (Lip) are known as anaerobic metabolism markers. They are repre-
sented as a doublet peak in the MR spectra at 1.31 ppm. It is important to note that lactate is 
not detected in healthy adult brain tissue. There is direct correlation between Lac level and 
glioma grade [3].
Malignant transformation of the glial tumors is usually accompanied by an increase in cell 
density with their relative ischemia resulting in a higher level of Lac. When ischemia of tumor-
ous tissue progresses further, the peaks of Lip increase, indicating the presence of necrosis 
and the destruction of myelin sheaths [7].
Thus, the level of Lip detected by MRS appears to reflect the severity of tissue damage.
2.6. Glutamate (Glu)-glutamine (Gln) and gamma-amino butyric acid
Glx is a complex peak from glutamate (Glu), glutamine (Gln), and gamma-amino butyric acid 
(GABA) assigned at 2.05–2.50 ppm [1].
These metabolite peaks are difficult to separate at 1.5 T. Glu is an important excitatory neu-
rotransmitter and plays a role in the redox cycle [8, 9].
An elevated concentration of Gln is found in a few conditions such as hepatic encephalopathy [9].
2.7. Alanine (Ala)
Alanine (Ala) is an amino acid and is a doublet peak assigned at 1.48 ppm.
This peak is located above the baseline in spectra obtained with short or long TE and inverts 
below the baseline at intermediate TE = 135–144 ms [1].
The function of Ala is uncertain; however, it plays a role in the citric acid cycle. Alanine peak 
may be obscured by lactate peak [8].
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An increased concentration of Ala may occur in oxidative metabolism defects [9].
In tumors, an elevated level of Ala is considered specific for meningiomas [1].
2.8. Other amino acids
In addition to alanine, other amino acids may be seen in various pathologies. Peaks of various 
amino acids may be seen at many levels, 0.9—valine and 3.6—leucine. Amino acids are also 
seen in abscesses and neurocysticercosis [10].
3. MRS in tumor grading
This is mainly used for glioma grading. Differentiation between low-grade and high-grade 
gliomas is important for estimating the prognosis and for therapeutic planning. Proton MRS 
may indicate the tumor grade with more accuracy because it assesses a larger amount of tis-
sue than what is usually excised during the biopsy.
Gliomas are heterogeneous and their spectra vary depending on the region sampled by 
MRS. Hence, the region of interest chosen for analysis has a higher influence on the results. 
Multivoxel spectroscopy is generally considered preferable because it allows metabolic het-
erogeneity to be evaluated in different components of the tumor.
3.1. Useful metabolites for suggesting the tumor grade
3.1.1. Choline
Statistically significant higher values of Cho/Cr and Cho/NAA are observed in high-grade 
than in low-grade gliomas.
Although the cutoff values of metabolite ratios for grading of gliomas are not well estab-
lished, Cho/Cr is the most frequently used ratio. Some institutions use a threshold value of 
2.0 for Cho/Cr to differentiate low-grade from high-grade gliomas; others use a cutoff value 
of 2.5.
Although increased Cho is related to tumor grade, few of grade IV gliomas have lower levels 
of Cho than grade II or grade III gliomas [11]. This may be due to the presence of necrosis in 
high-grade tumors, because necrosis is associated with a prominent lipid peak along with the 
reduction of rest other metabolites [12].
3.1.2. Lipids and lactates
The presence of lipids and lactates correlates with the necrosis in high-grade gliomas. 
High-grade and low-grade tumors and their margins could be differentiated based on the 
lactate/lipid peaks.
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Lipids peak is also found in metastasis. When lipids peak is observed in solid tumors, lym-
phoma should also be considered.
An increase in the lipid peak is inversely correlated to prognosis [12].
3.1.3. Myoinositol
Useful information on tumor grade can be obtained by assessing the myo levels at short TE 
(30–35 ms).
Myo/Cr ratio is typically higher in low-grade than in high-grade gliomas. This may be due to 
a low mitotic index leading to lack of activation phosphatidylinositol metabolism resulting in 
the accumulation of myo in low-grade gliomas.
In gliomas without alteration in Cho/Cr ratio, increased levels of Myo have been reported to 
be useful in the identification of low-grade tumors [12].
3.1.4. NAA and Cr
A greatest reduction in NAA and Cr levels has been observed in higher-grade tumors. As the 
grade of the tumor increases, NAA/Cr ratio decreases and Cho/NAA ratio increases.
4. Other applications of MRS in brain
4.1. Response to radiotherapy
Differentiation between recurrent brain tumor and radiation change/injury is an important 
concern in postradiotherapy patients with brain tumors and particularly when fresh contrast-
enhancing lesions are seen in previously operated and/or irradiated regions.
Proton MRS is useful in differentiating radiation-induced tissue injury from tumor recur-
rence. Significantly reduced Cho and Cr levels suggest radiation necrosis; increased lipid and 
lactate signals can also be seen in necrotic areas.
Increased Cho levels relative to the normal tissue suggest recurrence of the tumor. Cho/Cr and/
or Cho/NAA ratios are significantly higher in recurrent tumor than in radiation injury [12].
4.2. Infections
Pyogenic abscess: Amino acid peak at 0.9 ppm is useful in differentiating pyogenic abscess 
from tumors. Abscess from anaerobic organism in addition has acetate and succinate peaks at 
1.9 and 2.4 ppm, respectively [13] .
Tuberculous abscess: Spectra from tuberculous abscess shows lipid-lactate peak at 1.3 ppm. 
No amino acid peak is observed in tubercular abscess, which helps to differentiate it from 
pyogenic abscess [14].
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Fungal abscess: A spectrum in fungal abscesses shows amino acids and lactate peak along 
with multiple peaks between 3.6 and 4.0 ppm. These peaks have been assigned to trehalose 
sugar present in the fungal wall [15].
4.3. Metabolic brain disorder
Proton MR spectroscopy is a useful tool in diagnosing metabolic brain disorders when used 
as an adjunct to conventional MRI.
In most of the inherited metabolic disorders, MRS findings are abnormal but are not specific 
for a single metabolic disease or syndrome.
Few metabolic diseases have specific MRS findings, either abnormal elevation or reduction of 
a single normal peak or detection of abnormal metabolite peak.
Specific MRS patterns are mainly found in Canavan’s disease with prominently increased 
NAA peak and creatine deficiency with a characteristic reduced creatine peak. In nonketotic 
hyperglycemia, there is an appearance of glycine peak at 3.55 ppm and there is detection of 
branched-chain amino acids in maple syrup urine disease [16].
4.4. Dementia
Neurodegenerative dementia is characterized by elevated myoinositol and decreased 
N-acetylaspartate levels.
An increase in myoinositol occurs before the reduction of NAA levels in Alzheimer’s disease. 
An NAA/myo ratio in the posterior cingulate gyri decreases with an increasing burden of 
Alzheimer’s disease.
In patients with mild cognitive impairment, 1H MRS is sensitive in the detection of the patho-
physiologic processes associated with the risk of dementia [17].
4.5. Brain ischemia
The characteristic spectroscopic finding in acute brain ischemia is the early appearance of a 
lactate peak, a decrease of NAA, and a slight increase of choline. Lactate is observed within 
few minutes following brain ischemia and its concentration reduces in sub-acute phase. The 
intensity of these peaks in the infracted area is related to the prognosis [18].
4.6. Epilepsy
The role of 1H–MRS in epilepsy is to help in characterizing and localizing the epileptogenic 
focus, especially in patients with refractory focal epilepsy without clear MR imaging findings.
Temporal lobe epilepsy (TLE) is the most common cause of focal epilepsy; reduction in 
NAA concentration and NAA/Cho + Cr ratio is observed in TLE, which reflects the neuronal 
damage [1].
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5. Materials and methods
5.1. Study site
The study was conducted at the Department of Radio Diagnosis, Sri Sathya Sai Institute of 
Higher Medical Sciences, Whitefield, Bangalore 560066.
5.2. Study population
Initially, all patients suspicious for glioma and fulfilling the inclusion and exclusion criteria 
were imaged with conventional MRI and proton MR spectroscopy. All these patients underwent 
histopathological examination. Specimens were obtained via surgical resection/biopsy. Patients 
who had histopathological confirmation of glioma were included in the study. Histopathological 
grading was done according to WHO classification of brain tumors 2007 [19]. Grades I and II 
were graded as low-grade and grades III and IV were graded as high-grade tumors.
5.3. Study design
The study design was a prospective study.
5.4. Sample size
  Sample size =   Z 1−a/2 
2   SD 2 
 _______
 d 2 
 (1)
where Z
1-a/2
 is the standard normal variant; SD is the standard deviation of variable; d is the 
absolute error of precision.
The standard deviation of Cho/Cr for high-grade glioma is 1.92; Cho/Cr ratio is taken because 
for other ratios the sample size becomes very low. Absolute error of precision was 0.5.
  
Sample size 
 
=  (1.96) 2 ×  (1.92) 2  / 0.5 
   = 3.8 × 3.6 / 0.25  
 = 54.72 (rounded to 55) 
 (2)
The minimum sample size was around 55; we have included 70 patients.
5.5. Duration of the study
The duration of study was over a period of 14 months from 01-10-2014, to 01-02-2016.
5.6. Inclusion criteria
• All cases with neuroparenchymal space occupying lesions suspicious for gliomas on MRI.
• All age groups.
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• Both male and female patient population.
5.7. Exclusion criteria
• Postoperative and postradiotherapy patients.
• Unavailability of histopathological examination.
• MR spectroscopy with artifact, baseline noise, and uninterruptable spectra.
• MRI contraindicated patients:
 ○ Patients with cardiac pace maker
 ○ Patients with aneurysm clips in the brain
 ○ Patients with a metallic foreign body in the eye
 ○ Patients with severe claustrophobia
 ○ Pregnant patients
 ○ Mentally ill patients.
5.8. Methodology
• Concurrence was taken from the chairman, academic committee, scientific committee, and 
ethical committee for the study.
• Written informed consent was obtained prior to subject enrolment into the study.
• All the patients were subjected to conventional MRI and proton MR spectroscopy.
5.9. Magnetic resonance imaging
For all patients, initially MR imaging was performed with Siemens 1.5 T Magnetom Aera.
A localizing sagittal T1-weighted image was obtained followed by non-enhanced axial and 
coronal T2-weighted (4500/102 [TR/TE]), axial fluid-attenuated inversion-recovery (FLAIR, 
8500/86/2500 [TR/TE/TI]), and T1-weighted axial (600/9 [TR/TE]) images, Susceptibility weighted 
imaging (50/40 [TR/TE]). Contrast material-enhanced axial T1-weighted imaging was performed.
5.10. Magnetic resonance spectroscopy
After the conventional MRI volume of interest from the lesion (VOI) was selected from T1 
post-contrast images, VOI was selected from the solid part of lesion with edges of the voxel 
well within the mass and in most of the cases perilesional edema was included within the 
VOI. VOI was carefully selected so that it will not include areas of hemorrhage or calcification 
and unintended areas like ventricles, calvarium, and so on.
In our institution, we used Multivoxel MR spectroscopy technique (chemical shift method) at 
intermediate TE of −135 ms.
Clinical Application of MR Spectroscopy in Identifying Biochemical…
http://dx.doi.org/10.5772/intechopen.71728
115
A typical VOI consisted of an 8 × 8 cm region placed within a 16 × 16 cm field of view on a 
1.5-cm transverse section. A 16 × 16 phase-encoding matrix was used to obtain 8 × 8 arrays of 
spectra in the VOI, with an in-plane resolution of 1 × 1 cm and a voxel size of 1 × 1 × 1.5 cm3. 
The time taken to acquire spectra was around 8 min.
The metabolite peaks were assigned as follows: Cho, 3.22 ppm; Cr, 3.02 ppm; NAA, 2.02 ppm; 
lactate was identified at 1.33 ppm by its characteristic doublet and inversion at intermedi-
ate TE. Lipid peak was demonstrated at 0.9–1.3 ppm without inversion at intermediate 
TE. Metabolite ratios were obtained for Cho/Cr, Cho/NAA, NAA/Cr, and lactate/Cr. Maximal 
Cho/Cr, Cho/NAA and lactate/Cr and minimum NAA/Cr ratios were obtained from spec-
tral maps. Lactate/Cr was used instead of lipid-lactate/Cr used by other studies in literature 
because lipid peak was not consistently seen in most of the cases at intermediate TE.
5.11. Statistical methods
The data collected were entered into a Microsoft excel spreadsheet and analyzed using IBM SPSS 
Statistics, Version 22 (Armonk, NY: IBM Corp). Descriptive data were presented in the form of 
frequency, percentage, mean, median, standard deviation, and quartiles. The metabolite ratios of 
Cho/Cr, Cho/NAA, NAA/Cr, and lactate/Cr were calculated. The metabolite ratios between the 
low-grade and high-grade gliomas were compared using Mann–Whitney U-test. Comparisons 
of the categorical variables between the two groups were performed using the chi-squared test. 
Receiver-operating characteristic (ROC) curve analysis was done to evaluate the performance of 
the metabolite ratios in differentiating high-grade and low-grade gliomas. The area under the 
ROC curve was calculated to summarize the performance of each metabolite in differentiating 
the two grades of glioma. The sensitivity, specificity, positive-predictive value (PPV), negative-
predictive value (NPV), and diagnostic accuracy with each metabolite were assessed using the 
cutoff value obtained with minimum C1 error from the ROC analysis. A P-value of <0.05 was 
considered as statistically significant. In the same way, ROC curve analysis was done to evaluate 
the performance of metabolite ratios in differentiating grade II and grade III glioma. By similar 
way, sensitivity, specificity, positive-predictive value, negative-predictive value, and diagnostic 
accuracy with each metabolite were assessed using the cutoff value obtained with minimum C1 
error from the ROC analysis in differentiating grade II and grade III gliomas.
6. Results
Seventy histopathologically proved cases of gliomas were included in the study. Grade I [14] 
and grade II [19] gliomas were classified as low-grade and grade III [22] and grade IV [15] 
were classified as high-grade tumors.
All patients underwent conventional MRI sequences and proton MR spectroscopy. Quantitative 
values were calculated for Cho/Cr, Cho/NAA, NAA/Cr, and lactate/Cr ratios. Grading by conven-
tional MRI was also done to know the additional usefulness of MRS in grading of gliomas.
The sensitivity, specificity, PPV, and NPV of conventional MRI in grading of gliomas were 
62.2, 78.8, 76.7, and 65%, respectively, with the total diagnostic accuracy of 70%.
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The sensitivity, specificity, PPV, and NPV of proton MR spectroscopy in differentiating the 
grades of glioma were high in comparison to conventional MRI indicating that proton MRS 
spectroscopy is a useful tool in differentiating grades of glioma.
Lac/Cr ratio had a total diagnostic accuracy of 95.12%. Cho/NAA and Cho/Cr ratios had a 
total diagnostic accuracy of 88.57 and 88.43%, respectively.
Metabolite ratio that had the highest diagnostic value was lactate/Cr followed by Cho/NAA 
and Cho/Cr in differentiating low- and high-grade gliomas.
NAA/Cr ratio had poor diagnostic significance in differentiating the grades of gliomas.
The presence of lipid peak was found to be suggestive of high-grade gliomas and was found 
in about 46% of high-grade gliomas.
Other metabolite peaks like myoinositol and glutamate could not be evaluated.
MRS had the added advantage in combination with conventional MRI with good diagnostic 
accuracy in differentiating grade II and grade III gliomas. Lactate/Cr had the highest diagnos-
tic value followed by Cho/NAA and Cho/Cr in differentiating the two grades.
7. Discussion
Tumor grade is the most important key factor in determining treatment plan. Treatment 
plan for low-grade glioma is surgical resection; adjuvant radio chemotherapy is only recom-
mended for patients with incompletely resected grade II tumors or for patients older than age 
of 40 years. Whereas high-grade glioma always require chemotherapy and/or radiotherapy 
following surgery; therefore, preoperative grading of glioma is necessary for good patient 
care and to reduce the morbidity and mortality [19].
The current “gold standard” for the determination of glioma grade is histopathological 
examination. It has few limitations; the most significant one is limited number of samples 
which creates potential errors in determining the glioma grade. When samples are not taken 
from the most malignant region of tumor during biopsy or when the tumor has not been com-
pletely resected, histopathological grading becomes inaccurate. This problem is particularly 
observed in glioma because of the infiltrative and heterogeneous nature of these tumors; the 
region of highest malignancy may then be within the peritumoral or perilesional-enhancing 
region [20, 21].
Because histopathological examination requires biopsy/surgical resection which are invasive, 
it has morbidity of up to 3.6%, hemorrhage rate of up to 8%, and mortality of up to 1.7%, as 
assessed over a large number of studies [22].
Alternatively, many noninvasive or minimally invasive imaging technologies have been used 
to evaluate the malignancy of brain tumors [20, 21].
In our study, grades I and II were graded as low grade and grades III and IV were graded as 
high grade [19].
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We have used the following criteria for grading gliomas by conventional MRI: margins of 
the lesion, perilesional edema, heterogeneity of lesion, mass effect, crossing the midline, 
hemorrhage, necrosis, and enhancement pattern. Other studies have also used the similar 
criteria [21].
Sensitivity, specificity, PPV, and NPV of conventional MRI in grading of gliomas were found 
to be 62.2, 78.8, 76.7, and 65%, respectively, with the total diagnostic accuracy of 70%.
In other studies conducted by Law et al. [21], Zou et al. [19], and Ellika et al. [23], the sensitiv-
ity ranged from 72 to 86% and the specificity ranged from 60 to 67%.
Other studies in literature have shown sensitivity ranging from 55 to 83% [19, 21].
A study conducted by Dean et al. [24] and Atkinson et al. [25] showed that a high-grade 
glioma may be mistaken for a low-grade when it demonstrates minimal edema, no contrast 
enhancement, no necrosis, and no mass effect. Conversely, low-grade gliomas sometimes can 
be mistaken for a high-grade when it demonstrates peritumoral edema, contrast material 
enhancement, central necrosis, and mass effect.
Low diagnostic accuracy in our study was because of the overlapping imaging features in 
low- and high-grade gliomas, predominantly between grades II and grade III. Fourteen cases 
of grade III tumors were classified as low grade because they had imaging features favor-
ing low grade such as minimal perilesional edema, no significant mass effect, no contrast 
enhancement, no necrosis, and no hemorrhage.
Seven cases of low-grade gliomas were classified as high grade since they had imaging fea-
tures favoring high grade such as significant perilesional edema, mass effect, presence of 
necrosis or hemorrhage, and heterogeneous contrast enhancement.
In our study, the most consistent characteristics on MRI to predict the grade were necrosis, 
mass effect, and crossing the midline.
A study conducted by Dean et al. [24] has shown that mass effect and necrosis are the most 
important characteristic for predicting tumor grade by conventional MRI.
Because of the limitations of conventional MRI in differentiating high- from low-grade glio-
mas, advanced multi-parametric magnetic resonance techniques have been used in grading 
of gliomas and they are diffusion-weighted imaging (DWI), proton MR spectroscopy, and 
perfusion imaging [19].
Magnetic resonance spectroscopy is one of the advanced adjuvant MR techniques and because 
of its safe and noninvasive nature it is of great advantage in characterizing gliomas.
Because glial tumors have some specific metabolic characteristics which further differ accord-
ing to the grade, there is growing interest in MR spectroscopy that could further increase the 
sensitivity of routinely used diagnostic imaging [3].
In our study, we have used Cho/Cr, Cho/NAA, NAA/Cr, and lactate/Cr ratios for grading 
since the study was done at intermediate TE, prominent peaks seen were Cho, Cr, NAA, and 
lactate.
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In literature, Cho/Cr, Cho/NAA, and NAA/Cr were the commonly used metabolites [19, 21]. 
Lipid-lactate ratio was used for grading of gliomas in few studies [26]; we have used lactate/
Cr ration since lipid peak was not consistently seen in a majority of cases at intermediate TE.
In our study, the values of mean and median for Cho/Cr, Cho/NAA, and NAA/Cr had statisti-
cally significant difference between low- and high-grade gliomas.
Other studies have also shown significant difference of mean for Cho/Cr, Cho/NAA, and 
NAA/Cr between low- and high-grade gliomas [10].
NAA is a neuronal marker and decreases in all gliomas since the neurons are destroyed and/
or substituted by the malignant cells. The elevation of choline is due to the increased cellularity 
and cell membrane turnover. The decrease in creatine is due to the altered energy metabolism 
in the cells and can be attributed to the low energy status of the glycolyzing tumors. Therefore, 
the typical MRS characteristics of a glioma are elevated Cho with reduction in NAA and Cr 
signals. This results in an absolute increase in Cho/Cr and Cho/NAA and a decrease in NAA/
Cr ratios [1].
Lac/Cr ratio in our study had significant difference in mean between low- and high-grade 
gliomas.
Studies conducted by Yoon et al. [26] and Kim et al. [27] showed significant difference in mean 
values for lipid-lactate/Cr between low- and high-grade gliomas.
Since lactate is a marker of anaerobic glycolysis, malignant transformation of glial tumors is 
accompanied by an increase in cell density with relative ischemia resulting in a higher level 
of lactate. There is a direct correlation between Lac levels and glioma grade with higher peaks 
seen in higher-grade tumors [3]. Therefore, Lac/Cr ratio increases with an increase in the 
malignant potential of tumor.
In a clinical setting, where decisions such as the extent of tumor resection, the dose of post-
operative chemo radiation, and the interval of follow-up must be made, cutoff values can be 
used as important supplementary information in noninvasive grading of gliomas [21].
In our study, we have provided cutoff values for Cho/Cr, Cho/NAA, and lactate/Cr ratios to 
differentiate low- from high-grade gliomas.
A cutoff value of 1.76 for Cho/Cr and 2.22 for Cho/NAA ratio provided good sensitivity, 
specificity, PPV, and NPV with a total diagnostic accuracy of 78.05 and 82.93%, respectively, 
in differentiating low- from high-grade gliomas.
Other studies in literature have given a cutoff value ranging from 1.56 to 2.04 for Cho/Cr and 
1.6 to 2.49 for Cho/NAA. These values provided good sensitivity, specificity, PPV, and NPV 
with a total diagnostic accuracy ranging from 81 to 88% [21].
Even though the cutoff value for Cho/Cr and Cho/NAA provided by our study was compa-
rable with other studies in literature [21], the small variation in cutoff value between studies 
is possibly because of differences in the MRS imaging methods, including magnetic resonance 
field strength, acquisition parameters, voxel size and location, heterogeneity of tumor, and 
sample size and distribution.
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A cutoff value of 0.68 for Lac/Cr ratio provided an excellent diagnostic accuracy of 95.12% 
which was the most useful metabolite ratio in differentiating low- from high-grade gliomas 
in our study.
Limited studies in literature have given cutoff for lipid-lactate/Cr ratio in grading of gliomas. A 
study performed by Kim et al. gave a cutoff value of 0.59 for lipid-lactate/Cr [28]. A study per-
formed by Yoon et al. gave a cutoff of 1.39 with a sensitivity of 64.6% and a specificity of 91.7% [26].
There was no cutoff value given for NAA/Cr ratio in our study even though the mean values 
were statistically significant in differentiating high- and low-grade gliomas because of over-
lapping of NAA/Cr values between the grades; out of 37 people in high-grade gliomas, 29 
(78% of high-grade glioma cases) had values higher than the lowest value in low grade.
Zeng et al. [28] and Liu et al. [29] have given cutoff values of 0.72 and 0.97 for NAA/Cr ratio to 
differentiate low- and high-grade gliomas with a diagnostic accuracy of 73–75%.
In our study, lipid peak was found in 46% of high-grade and 12% of low-grade gliomas. A 
prominent lipid peak in high-grade gliomas was due to necrotic component.
Other studies have also shown that gliomas are heterogeneous tumors and they include areas 
of viable tumor, necrosis, and hemorrhage. Elevated lipid peaks are often found in high-grade 
gliomas due to the necrotic portion [30, 31].
Since our study is carried out at intermediate TE (135 ms), we could not evaluate other peaks 
like myoinositol and glutamate. Few cases had myoinositol peak but the peak was not consis-
tently seen to comment upon.
Differentiation between grade II and III gliomas is clinically important since the treatment 
plan and prognosis are different but it is difficult to differentiate them on conventional MRI 
because of the overlapping imaging characteristics [32].
Literature review showed limited studies to differentiate grade II and grade III gliomas. In 
our study, we analyzed and tried to establish cutoff values to differentiate grade II and grade 
III gliomas.
Lactate/Cr had excellent diagnostic value followed by Cho/NAA and Cho/Cr ratios. NAA/Cr 
had poor diagnostic value in differentiating the grade II and grade III because of the overlap-
ping of values.
Cutoff values for Cho/Cr, Cho/NAA, and lactate/Cr ratios were 1.76, 2.22, and 0.685 with good 
sensitivity, specificity, PPV, and NPV. Diagnostic accuracy was 78.05, 82.93, and 95.12% for 
Cho/Cr, Cho/NAA, and lactate/Cr, respectively.
Stadlbauer et al. [23] found that there was significant difference in Cho, Cr, and NAA levels 
between grade II and grade III gliomas, and all patients with a grade II glioma had a Cho/
NAA ratio of less than 0.8, whereas all patients with a grade III glioma had a Cho/NAA ratio 
of greater than 0.8.
Zonari et al. [33] found the sensitivity, specificity, PPV, and NPV for Cho/Cr ratio to be 75.6 45, 
60.7, and 62.1 and NAA/Cr ratio to be 64.4, 65, 67.4, and 61.9 in differentiating grade II from 
grade III gliomas by a logistic regression analysis.
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Advanced multi-parametric magnetic resonance techniques, including DWI, DTI, and MR 
perfusion and multimodal imaging including PET/SPECT, also compliment MRS to distin-
guish HGGs from LGGs. Though it is controversial which imaging technique is superior, most 
authors concluded that combined techniques would improve the diagnostic accuracy [19].
8. Limitations
1. Our study was done at a magnetic field strength of 1.5 T. A higher-field strength of 3 T or 
more would have yielded a better spatial resolution and high SNR.
2. Small sample size may reduce or bias the power of the results. Further studies with a larger 
sample size are necessary to extend these results.
3. Our sample volume predominantly consists of astrocytomas, and other glial tumors like 
oligodendrogliomas and ependymomas were less frequent.
4. Our study was carried at intermediate TE, so we could not evaluate smaller metabolite 
peaks like myoinositol and glutamate. MRS at short TE would have given spectra with 
multiple metabolite peaks.
5. Comparison of MRS with other advanced MR techniques like perfusion and DTI would 
have given additional value in grading of gliomas.
9. Conclusion
MRS is an important diagnostic and research tool in clinical neuroscience. MRS is a very 
useful tool in combination with conventional MRI for grading of gliomas. Lactate/creatine 
ratio has highest diagnostic accuracy followed by choline/NAA and choline/creatine ratios. 
NAA/creatine has least diagnostic significance in grading of gliomas. Lipid peak on MRS is 
more frequently found in high-grade gliomas. MRS could differentiate grade II and grade III 
gliomas more effectively in comparison to only conventional MRI. Apart from tumor grading, 
MRS can support the diagnosis in many brain infections by showing the specific metabo-
lite peaks. It is also helpful in diagnosis of post-radiotherapy patients when differentiation 
between recurrent brain tumor and radiation change/injury is the concern. It also has a sig-
nificant role in narrowing the differential diagnosis of metabolic brain disorders. MRS is also 
important in the diagnosis of stroke and demyelination in brain.
A. Appendix A
A.1. Representative cases
Case 1. A 46-year-old female presented with headache since 1 year.
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MRI shows well-defined cystic lesion with enhancing peripheral mural nodule in the right 
cerebellar hemisphere with mild perilesional edema. Local mass effect on the adjacent neuro-
parenchyma. No areas of hemorrhage on SWI. No areas of necrosis.
Diagnosed as low-grade glioma on conventional MRI.
MRS: Elevated choline, reduced NAA, and Cr. Cho/Cr: 1.63; Cho/NAA: 1; NAA/Cr: 1.09; lac-
tate/Cr: 0.18. No lipid peak.
Histopathological diagnosis: Pilocytic astrocytoma (grade I glioma).
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Case 2: A 70-year-old male presenting with seizures since 2 months.
MRI shows relatively well-defined heterogeneous lesion noted in the left parietal lobe with 
moderate perilesional edema. There is mass effect on the adjacent neuroparenchyma without 
midline shift. Areas of necrosis and hemorrhage noted within the lesion. Peripheral nodular 
enhancement is seen.
Diagnosed as high-grade glioma on conventional MRI.
Relatively well-defined heterogeneous lesion noted in the left parietal lobe with moderate perile-
sional edema. There is mass effect on the adjacent neuroparenchyma without midline shift. Areas 
of necrosis and hemorrhage noted within the lesion. Peripheral nodular enhancement is seen.
Diagnosed as high-grade glioma on conventional MRI.
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MRS: Elevated choline, reduced NAA, and Cr.
Cho/Cr: 2.47; Cho/NAA: 3.5; NAA/Cr: 0.7; lactate/Cr: 1.
Lipid peak present.
Histopathological diagnosis: GBM (grade IV glioma).
Paraffin section with hematoxylin and eosin stain showing marked nuclear pleomorphism 
and mitotic figures.
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